Overview

A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer

Status:
RECRUITING
Trial end date:
2027-01-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to determine the pharmacokinetics (PK) and pharmacodynamics (PD) of Debio 4228.
Phase:
PHASE2
Details
Lead Sponsor:
Debiopharm International SA